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Astronauts lose 1.0 to 1.5% of their
bone mass per month on long-duration
spaceflights. NASA wishes to monitor
the bone loss onboard spacecraft to de-
velop nutritional and exercise counter-
measures, and make adjustments during
long space missions. On Earth, the same
technology could be used to monitor os-
teoporosis and its therapy.
Aptamers bind to targets against which
they are developed, much like antibodies.
However, aptamers do not require animal
hosts or cell culture and are therefore
easier, faster, and less expensive to pro-
duce. In addition, aptamers sometimes
exhibit greater affinity and specificity vs.
comparable antibodies. In this work, flu-
orescent dyes and quenchers were added
to the aptamers to enable pushbutton,
one-step, bind-and-detect fluorescence
resonance energy transfer (FRET) assays
or tests that can be freeze-dried, rehy-
drated with body fluids, and used to
quantitate bone loss of vitamin D levels
with a handheld fluorometer in the
spacecraft environment.
This work generated specific, rapid,
one-step FRET assays for the bone loss
marker C-telopeptide (CTx) when ex-
tracted from urine, creatinine from
urine, and vitamin D congeners in di-
luted serum. The assays were quantified
in nanograms/mL using a handheld flu-
orometer connected to a laptop com-
puter to convert the raw fluorescence
values into concentrations of each ana-
lyte according to linear standard curves.
DNA aptamers were selected and am-
plified for several rounds against a 26-
amino acid form of CTx, creatinine, and
vitamin D. The commonalities between
loop structures were studied, and several
common loop structures were converted
into aptamer beacons with a fluo-
rophore and quencher on each end. In
theory, when the aptamer beacon binds
its cognate target (CTx bone peptide,
creatinine, or vitamin D), it is forced
open and no longer quenched, so it
gives off fluorescent light (when ex-
cited) in proportion to the amount of
target present in a sample. This propor-
tional increase in fluorescence is called a
“lights on” FRET response. The vitamin
D aptamer beacon gives a “lights off” or
inversely proportional fluorescence re-
sponse to the amount of vitamin D pres-
ent in diluted serum.
These FRET-aptamer assays are rapid
(<30 minutes), sensitive (low ng/mL de-
tection limits), and quite easy to carry
out (add sample, mix, and detect in the
handheld reader). Benefits include the
speed of the assays as well as the small
amount of space taken up by the hand-
held reader and cuvette assays. 
The aptamer DNA sequences repre-
sent novel additional features of the ex-
isting (patent-pending) FRET-aptamer
assay platform.
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Applications include assessment of osteoporosis, and aptamer assays for veterinary analytes,
infectious disease, food- and water-borne pathogens, and chemical/biological threats. 
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